Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$3.98
+0.4%
$3.55
$2.57
$6.88
$24.59M0.642,828 shs1,379 shs
NanoViricides, Inc. stock logo
NNVC
NanoViricides
$1.44
+5.1%
$1.50
$0.94
$2.07
$23.14M0.96242,025 shs109,767 shs
Passage Bio, Inc. stock logo
PASG
Passage Bio
$7.54
+1.9%
$6.92
$5.12
$26.60
$23.97M1.8158,174 shs47,497 shs
Psyence Biomedical Ltd. stock logo
PBM
Psyence Biomedical
$3.24
+1.3%
$5.07
$2.36
$319.20
$6.05M0.224.99 million shs77,440 shs
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.00%+3.52%+8.90%+18.66%-27.73%
NanoViricides, Inc. stock logo
NNVC
NanoViricides
0.00%-4.00%-15.79%-19.55%-28.89%
Passage Bio, Inc. stock logo
PASG
Passage Bio
0.00%+8.49%+31.59%+1.89%-49.51%
Psyence Biomedical Ltd. stock logo
PBM
Psyence Biomedical
0.00%-0.92%-67.57%-26.20%-98.96%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/AN/AN/AN/AN/AN/AN/AN/A
NanoViricides, Inc. stock logo
NNVC
NanoViricides
0.73 of 5 stars
0.05.00.00.02.50.00.0
Passage Bio, Inc. stock logo
PASG
Passage Bio
3.788 of 5 stars
3.55.00.00.02.62.51.3
Psyence Biomedical Ltd. stock logo
PBM
Psyence Biomedical
1.1758 of 5 stars
0.05.00.00.01.11.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.00
N/AN/AN/A
NanoViricides, Inc. stock logo
NNVC
NanoViricides
0.00
N/AN/AN/A
Passage Bio, Inc. stock logo
PASG
Passage Bio
3.00
Buy$91.751,116.84% Upside
Psyence Biomedical Ltd. stock logo
PBM
Psyence Biomedical
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest PBM, NAII, NNVC, and PASG Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/14/2025
Passage Bio, Inc. stock logo
PASG
Passage Bio
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$260.00 ➝ $67.00
8/13/2025
Passage Bio, Inc. stock logo
PASG
Passage Bio
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$40.00
6/24/2025
Passage Bio, Inc. stock logo
PASG
Passage Bio
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$120.00
(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$113.80M0.22N/AN/A$13.32 per share0.30
NanoViricides, Inc. stock logo
NNVC
NanoViricides
N/AN/AN/AN/A$0.66 per shareN/A
Passage Bio, Inc. stock logo
PASG
Passage Bio
N/AN/AN/AN/A$12.04 per shareN/A
Psyence Biomedical Ltd. stock logo
PBM
Psyence Biomedical
N/AN/A$1.79 per share1.81$11.83 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
-$7.22M-$1.39N/AN/A-6.56%-10.34%-5.19%9/26/2025 (Estimated)
NanoViricides, Inc. stock logo
NNVC
NanoViricides
-$8.29M-$0.70N/AN/AN/A-87.90%-78.69%N/A
Passage Bio, Inc. stock logo
PASG
Passage Bio
-$64.77M-$18.16N/AN/AN/AN/A-103.87%-59.95%11/12/2025 (Estimated)
Psyence Biomedical Ltd. stock logo
PBM
Psyence Biomedical
$1.01MN/A0.00N/AN/AN/AN/AN/A

Latest PBM, NAII, NNVC, and PASG Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
Passage Bio, Inc. stock logo
PASG
Passage Bio
-$4.00-$2.96+$1.04-$2.96N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/AN/AN/AN/AN/A
NanoViricides, Inc. stock logo
NNVC
NanoViricides
N/AN/AN/AN/AN/A
Passage Bio, Inc. stock logo
PASG
Passage Bio
N/AN/AN/AN/AN/A
Psyence Biomedical Ltd. stock logo
PBM
Psyence Biomedical
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.11
2.51
1.35
NanoViricides, Inc. stock logo
NNVC
NanoViricides
N/A
3.44
2.47
Passage Bio, Inc. stock logo
PASG
Passage Bio
N/A
3.05
3.05
Psyence Biomedical Ltd. stock logo
PBM
Psyence Biomedical
N/A
11.04
11.04

Institutional Ownership

CompanyInstitutional Ownership
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
32.40%
NanoViricides, Inc. stock logo
NNVC
NanoViricides
10.30%
Passage Bio, Inc. stock logo
PASG
Passage Bio
53.48%
Psyence Biomedical Ltd. stock logo
PBM
Psyence Biomedical
77.44%

Insider Ownership

CompanyInsider Ownership
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
20.90%
NanoViricides, Inc. stock logo
NNVC
NanoViricides
4.60%
Passage Bio, Inc. stock logo
PASG
Passage Bio
5.00%
Psyence Biomedical Ltd. stock logo
PBM
Psyence Biomedical
3.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
2906.18 million4.89 millionNot Optionable
NanoViricides, Inc. stock logo
NNVC
NanoViricides
2016.07 million14.92 millionOptionable
Passage Bio, Inc. stock logo
PASG
Passage Bio
1303.18 million3.02 millionOptionable
Psyence Biomedical Ltd. stock logo
PBM
Psyence Biomedical
N/A1.87 million1.80 millionN/A

Recent News About These Companies

Pacific Bay Warrant Extension Not Proceeding
Psyence Biomedical Ltd. Wt
Psyence Group consolidates its shares

New MarketBeat Followers Over Time

Media Sentiment Over Time

Natural Alternatives International stock logo

Natural Alternatives International NASDAQ:NAII

$3.95 -0.01 (-0.23%)
As of 08/22/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Natural Alternatives International, Inc. engages in formulating, manufacturing, and marketing nutritional supplements in the United States, Europe, Australia, Asia, Mexico, and Canada. The company operates in two segments, Private-Label Contract Manufacturing, and Patent and Trademark Licensing. It offers private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbal, and other nutritional supplements, as well as other health care products. The company also provides strategic partnering services, such as customized product formulation, clinical study design and support, manufacturing, marketing support, international regulatory and label law compliance, international product registration, packaging in multiple formats and labeling design, scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management, packaging and delivery system design, regulatory review, and international product registration assistance. In addition, it sells beta-alanine ingredient under the CarnoSyn and SR CarnoSyn names. The company manufactures products in various forms, including capsules, tablets, chewable wafers, and powders. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer e-commerce channels, and retail stores. The company was founded in 1980 and is headquartered in Carlsbad, California.

NanoViricides stock logo

NanoViricides NYSE:NNVC

$1.44 +0.07 (+5.11%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$1.46 +0.02 (+1.67%)
As of 08/22/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases. It also offers NV-CoV-2 Solution for injection, infusion, and inhalation to treat severe cases that are not yet hospitalized would be best performed by an injection; and injectable solution can be delivered directly into the lungs as a fog created using standard portable battery operated nebulizer devices which enables action at the most important site of infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company provides Nanoviricide, a biomimetic platform technology designed to attack enveloped virus particles to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.

Passage Bio stock logo

Passage Bio NASDAQ:PASG

$7.54 +0.14 (+1.89%)
Closing price 08/22/2025 03:59 PM Eastern
Extended Trading
$7.54 0.00 (-0.07%)
As of 08/22/2025 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Psyence Biomedical stock logo

Psyence Biomedical NASDAQ:PBM

$3.24 +0.04 (+1.25%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$3.24 +0.00 (+0.15%)
As of 08/22/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.